Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising outcomes in initial clinical assessments . Current https://johsocial.com/story12022940/retatrutide-emerging-research-and-possible-medical-roles